Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -123.71% is 41% above its 5-year average of -208.85%, near the high end of its 5-year range (-65066.67%–13.70%).
99.07% above its 12-month average of -13251.09%.
Reported quarterly EBITDA margin; no daily interpolation. Q4 FY2024 (2024-12-31): -65066.67%.
EBITDA MARGIN
-123.71%
EBITDA MARGIN AVG TTM
-13251.09%
EBITDA MARGIN AVG 3Y
-292.28%
EBITDA MARGIN AVG 5Y
-208.85%
EBITDA MARGIN AVG 10Y
-509.25%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+99.07%
CURRENT VS 3Y AVG
+57.67%
CURRENT VS 5Y AVG
+40.77%
CURRENT VS 10Y AVG
+75.71%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Pulmatrix, Inc.
Market Cap
$5.22M
EBITDA Margin
-123.71%
TTM Avg
-13251.09%
3Y Avg
-292.28%
5Y Avg
-208.85%
Market Cap
$5.24M
EBITDA Margin
-271.50%
TTM Avg
-294.22%
3Y Avg
-453.19%
5Y Avg
-366.18%
Market Cap
$5.20M
EBITDA Margin
-2579.35%
TTM Avg
-2579.35%
3Y Avg
-2089.74%
5Y Avg
-2089.74%
Market Cap
$5.35M
EBITDA Margin
-5685.74%
TTM Avg
-22429.68%
3Y Avg
-11536.25%
5Y Avg
-7742.59%
Market Cap
$5.03M
EBITDA Margin
-8.85%
TTM Avg
9.13%
3Y Avg
18.32%
5Y Avg
18.32%
Market Cap
$5.02M
EBITDA Margin
-1670.57%
TTM Avg
-1446.66%
3Y Avg
-2067.25%
5Y Avg
-1679.39%
Market Cap
$5.02M
EBITDA Margin
-4837.99%
TTM Avg
-4449.42%
3Y Avg
-4104.15%
5Y Avg
-4023.55%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pulmatrix, Inc. (PULM) | $5.22M | -123.71% | -13251.09% | -292.28% | -208.85% |
| Lunai Bioworks Inc. (LNAI)vs › | $5.21M | N/A | N/A | N/A | N/A |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.24M | -271.50% | -294.22% | -453.19% | -366.18% |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.20M | -2579.35% | -2579.35% | -2089.74% | -2089.74% |
| Alzamend Neuro Inc (ALZN)vs › | $5.29M | N/A | N/A | N/A | N/A |
| Soligenix, Inc. (SNGX)vs › | $5.35M | -5685.74% | -22429.68% | -11536.25% | -7742.59% |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.03M | -8.85% | 9.13% | 18.32% | 18.32% |
| Lexaria Bioscience Corp. (LEXX)vs › | $5.02M | -1670.57% | -1446.66% | -2067.25% | -1679.39% |
| Imunon, Inc. (IMNN)vs › | $5.02M | -4837.99% | -4449.42% | -4104.15% | -4023.55% |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.00M | N/A | N/A | N/A | N/A |
Gross Margin
0.0%
EBITDA Margin
-123.7%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2024-12-31 | -65066.67% |
| 2024-09-30 | -725.96% |
| 2024-06-30 | -377.19% |
| 2024-03-31 | 13.70% |
| 2023-12-31 | -99.32% |
| 2023-09-30 | -222.88% |
| 2023-06-30 | -214.70% |
| 2023-03-31 | -303.74% |
| 2022-12-31 | -250.94% |
| 2022-09-30 | -270.25% |
| 2022-06-30 | -338.99% |
| 2022-03-31 | -424.83% |
| 2021-12-31 | -878.95% |
| 2021-09-30 | -761.83% |
| 2021-06-30 | -169.12% |
| 2021-03-31 | -290.22% |
| 2020-12-31 | -130.80% |
| 2020-09-30 | -27.97% |
| 2020-06-30 | -32.06% |
| 2020-03-31 | -169.66% |
| 2019-12-31 | -241.48% |
| 2019-09-30 | -258.32% |
| 2019-06-30 | -163.98% |
| 2018-03-31 | -3303.27% |
| 2017-09-30 | -1267.16% |
| 2016-12-31 | -6317.09% |
| 2016-09-30 | -4803.28% |
| 2016-06-30 | -3427.31% |
| 2016-03-31 | -1359.85% |
| 2015-12-31 | -1542.18% |
| 2015-09-30 | -707.22% |
| 2015-06-30 | -6622.94% |
| 2015-03-31 | -2557.14% |
| 2014-12-31 | -485.99% |
| 2014-09-30 | -8370.00% |
| 2014-03-31 | -29125.00% |
